We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03947567
Recruitment Status : Recruiting
First Posted : May 13, 2019
Last Update Posted : April 28, 2020
Information provided by (Responsible Party):
Sinocelltech Ltd.

Brief Summary:
This study is a multi-center, open-label, extension trial to evaluate the safety, efficacy of SCT800 in long term prophylaxis and on-demand treatment in patients with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from V1, on-demand treatment is given when bleeding episodes occur. The study period is 120 consecutive weeks.

Condition or disease Intervention/treatment Phase
Hemophilia A Drug: Recombinant Human Coagulation FVIII Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicenter, Open, Extension Trial to Evaluate Safety and Efficacy of Recombinant Human Coagulation Factor VIII (SCT800) During Long Term Treatment in Previously Treated Patients With Severe Haemophilia A .
Actual Study Start Date : July 26, 2019
Estimated Primary Completion Date : April 1, 2025
Estimated Study Completion Date : April 1, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia

Arm Intervention/treatment
Experimental: Recombinant Human Coagulation FVIII Drug: Recombinant Human Coagulation FVIII
Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
Other Name: SCT800

Primary Outcome Measures :
  1. Incidence of FVIII inhibitors [ Time Frame: up to 120 weeks ]
    The Nijmegen-Bethesda assay shall be used to monitor the production of FVIII inhibitors during the trial.

Secondary Outcome Measures :
  1. Annualized Bleeding Rate [ Time Frame: up to 120 weeks ]
    Annualized Bleeding Rate(ABR) can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25)

  2. FVIII incremental in-vivo recovery [ Time Frame: up to 120 weeks ]
    Incremental recovery is determined as the peak factor level recorded in the first hour after infusion and is reported as [IU/ml]/[IU/kg]

  3. Bleeding event treatment efficacy [ Time Frame: up to 120 weeks ]
    The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Hemophilia A is a kind of sex chromosome recessive genetic disease and ofter occurs in male.
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male patients who are diagnosed with severe (laboratory tested FVIII:C <2%) hemophilia A;
  • Patients Who Completed trial of SCT800-A302 or SCT800-A 303 and New PTP(previously treated patients)(Previously received FVIII prophylactic or bleeding treatment, have the relevant records and are verified to have accumulated exposures days( EDs) ≥150 days;
  • Negative FVIII inhibitor assay results (laboratory tested Nijmegen-Bethesda assay result <0.6 BU(Bethesda unit)/mL);
  • The treatment records of at least 50EDs before screening can be obtained;
  • HIV negative; if HIV positive, the viral load <200 particles/uL or <400,000 copies/mL, and HIV patients must satisfy CD4+ count >200/μL;
  • The patient or his guardian voluntarily signed the Informed Consent Form.

Exclusion Criteria:

  • Known allergy to any coagulation factor VIII or any excipient; known allergy to bovine, rodent or hamster bovine;
  • Has a history or family history of blood coagulation factor VIII inhibitor;
  • Patients with other coagulation dysfunction diseases in addition to hemophilia A;
  • Patients with other clinically significant diseases, alcoholism, drug abuse, mental disorders or intellectual disabilities;
  • Patients with other severe or clinical significant diseases verified by the investigator to be unable to benefit from the clinical study;
  • Patients who participated in other clinical studies within one month before the first drug administration (except FVIII trials) and patients who participated in other FVIII clinical trials after signing the Informed Consent Form;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03947567

Layout table for location contacts
Contact: Renchi Yang 13512078851 rcyang65@163.com
Contact: Feng Xu

Layout table for location information
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Recruiting
Tianjin, China
Contact: Renchi Yang         
Sponsors and Collaborators
Sinocelltech Ltd.
Layout table for investigator information
Principal Investigator: Renchi Yang Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Layout table for additonal information
Responsible Party: Sinocelltech Ltd.
ClinicalTrials.gov Identifier: NCT03947567    
Other Study ID Numbers: SCT800-A401
First Posted: May 13, 2019    Key Record Dates
Last Update Posted: April 28, 2020
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn